This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Supernus Pharmaceuticals Braces for 2025 U.S. Drug Pricing Orders and MFN Rules That Threaten Revenues and Global Expansion
Supernus Pharmaceuticals (SUPN) has disclosed a new risk, in the Employment / Personnel category.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Supernus Pharmaceuticals faces heightened uncertainty as 2025 U.S. Executive Orders targeting lower drug prices could pressure net revenues from its commercial portfolio if reimbursement benchmarks decline. Moreover, MFN-style pricing frameworks may constrain its global expansion strategy, as entering lower-priced foreign markets could reset unfavorable U.S. reference prices and dampen long-term growth.
The average SUPN stock price target is $62.17, implying 13.95% upside potential.
To learn more about Supernus Pharmaceuticals’ risk factors, click here.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
